Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.3%

5 terminated out of 80 trials

Success Rate

89.6%

+3.1% vs benchmark

Late-Stage Pipeline

11%

9 trials in Phase 3/4

Results Transparency

23%

10 of 43 completed with results

Key Signals

10 with results90% success

Data Visualizations

Phase Distribution

60Total
Not Applicable (36)
P 1 (8)
P 2 (7)
P 3 (9)

Trial Status

Completed43
Unknown12
Recruiting10
Active Not Recruiting6
Terminated5
Withdrawn3

Trial Success Rate

89.6%

Benchmark: 86.5%

Based on 43 completed trials

Clinical Trials (80)

Showing 20 of 20 trials
NCT07287189Phase 2Recruiting

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

NCT03698149Not ApplicableRecruiting

ECoG BMI for Motor and Speech Control

NCT01568658Active Not RecruitingPrimary

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

NCT07558213Active Not Recruiting

A Multi-Dimensional Model of cAre and transItion for Patients With cOmplex RAre Diseases

NCT07250737Unknown

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

NCT05747924Phase 1Completed

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05199246Not ApplicableCompletedPrimary

Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders

NCT05200702Not ApplicableCompletedPrimary

Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders

NCT07521930Not ApplicableRecruiting

Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)

NCT07502989Recruiting

Muscle Health Measurements Using Electrical Impedance Myography

NCT04694456Not ApplicableCompletedPrimary

Pro-inflammatory Cytokines in Facioscapulohumeral Muscular Dystrophy (CYTOKINE-FSH)

NCT03179631Phase 3Completed

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

NCT03981289Completed

Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD)

NCT06666816RecruitingPrimary

Observational Study to Observe Variations of Gait Parameters in Patients With Neuromuscular Diseases

NCT05126758Phase 3Active Not RecruitingPrimary

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

NCT05724173Not ApplicableRecruiting

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

NCT06094205Not ApplicableRecruiting

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)

NCT05479981Phase 2Completed

Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients

NCT07129954Not ApplicableRecruiting

Fear of Falling in Muscular Dystrophy

NCT05257473Active Not Recruiting

Defining Endpoints in Becker Muscular Dystrophy

Scroll to load more

Research Network

Activity Timeline